Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on ￃﾢ￢ﾂﾬￋﾜfinding the bugￃﾢ￢ﾂﾬ￢ﾄﾢ are (1) slow and (2) effective in fewer than 30% of cases. Inflammatixￃﾂￂﾠhas developed a statistically rigorous,ￃﾂￂﾠextensively validated diagnostic method that 'reads' the immune system. Our HostDxￃﾢ￢ﾀﾞￂﾢ tests report clinically actionable information on theￃﾂￂﾠpresence, type (bacterial or viral), and severity of infection in all patients. They have been extensively validated and published in top-tier medical journals. After this initial product, Inflammatix plans to develop and commercialize additional novel diagnostic tests to address significant unmet clinical needs.

Aisera offers the world's first AI-driven service experience solution that automates operations and support for IT, Sales and customer service, making businesses and customers successful by offering consumer-like self-service resolutions to users. Aisera fast tracks the digital transformation journey with user and service behavioral intelligence that drives end-to-end automation of tasks, actions, and business processes. Aisera is a top-tier, VC-funded startup headquartered in Palo Alto, Calif. and a strategic partner with AWS, Microsoft Azure, Google Cloud, ServiceNow and Salesforce. Aisera has received numerous recognitions, including the following: Forbes AI50; CNBC Upstart 100 Top Startup; Gartner Cool Vendor 2019; Red Herring Top 100 Global Innovator; 2019 CIO Innovation Startup Award; CIO Review Top ITSM Solution; Aragon Research 2019 Hot Vendor; TiE50 2019 Startup Award; and Silicon Review 50 Most Admired Companies for 2019.